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Abstract
PURPOSE—Community-based testing may identify young adults in the general population with
sexually transmitted chlamydial infection. To develop selective screening guidelines appropriate for
community settings, the authors conducted a cross-sectional analysis of the National Longitudinal
Study of Adolescent Health Wave III (April 2, 2001 – May 9, 2002).
METHODS—Separately for women and men, we developed three predictive models using
unconditional multiple logistic regression for survey data. To account for racial/ethnic disparity in
prevalence, initial models included identical predictor characteristics plus information on 1)
respondent’s race/ethnicity; or 2) respondent’s most recent partner’s race/ethnicity; or 3) no
information on race/ethnicity.
RESULTS—C. trachomatis diagnosis was available for 10,928 (88.6%) of the sexually experienced
respondents. A combination of five characteristics for women and six characteristics for men
identified approximately 80% of infections while testing ≤50% of the population. Information
regarding race/ethnicity dramatically affected algorithm performance.
CONCLUSION—Using race/ethnicity in any screening algorithm is problematic and controversial,
but the model without race information missed many diagnoses in the minority groups. Universal
screening in high prevalence regions and selective screening in low prevalence regions may be one
method of reaching the affected populations while avoiding the stigma of guidelines incorporating
race/ethnicity.
Chlamydia trachomatis, with an estimated three million new infections each year, is the most
common bacterial sexually transmitted infection (STI) in the United States (US), especially
among adolescents and young adults (1). Black, Native American, and Latino women and men
are disproportionately burdened with infection (2). Although predominately asymptomatic
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(3,4) chlamydial infection may cause pelvic inflammatory disease, ectopic pregnancy, and
tubal infertility in women (5–7). Chlamydial infection increases susceptibility to and
transmission of HIV in women and men (8,9).
Testing and treatment for chlamydial infection can lower the prevalence of infection (10–12)
and the incidence of pelvic inflammatory disease (13). The US Preventive Services Task Force
“strongly recommends” that clinicians routinely screen all sexually active women aged 25
years or younger for chlamydial infection (14). Screening rates, however, remain low (15,16)
despite the inclusion of chlamydial screening in the Health Plan Employer Data and
Information Set performance measures (17). Furthermore, chlamydial infection in men is only
just being addressed by the newest recommendations (18).
Expanding screening from clinic to community settings may increase screening, particularly
among minority populations experiencing high prevalence and limited access to care.
Community-based screening may also facilitate testing men. Selective screening criteria to
identify individuals at greatest risk of infection may help make such programs logistically and
economically feasible (19,20). In community settings, screening guidelines should be based
on data from the general population, rather than algorithms derived from clinical data. Wave
III of the National Longitudinal Study of Adolescent Health (Add Health) was used to develop
criteria for screening young women and men in the US general population for prevalent
chlamydial infection.
MATERIALS AND METHODS
Study design and sample
Add Health is a prospective cohort study that has followed nearly 20,000 adolescents into
adulthood over three waves of data collection (21). For this study, we conducted a cross-
sectional analysis of Wave III (April 2, 2001 to May 9, 2002), which targeted all Wave I
participants. Our study population was restricted to Wave III participants responding “Yes”
when asked “Have you ever had vaginal intercourse?” The University of North Carolina
institutional review board approved all study procedures.
The two-stage sampling of Add Health has been described in detail elsewhere (21,22). Briefly,
a systematic random sample of secondary schools was chosen to ensure that the schools were
representative of all US secondary schools with respect to key characteristics. The original
participants were identified from students in grades seven through 12. Oversampling some
black and Latino students enhanced precision of estimates for these groups. Post-stratification
sampling weights adjusted for persons who did not participate in Wave III. After accounting
for design effect, the Add Health Wave III cohort provides a representative sample of young
adults aged 18 to 26 years living in the US.
Interview and specimen collection
For non-sensitive issues, the interviewer recorded responses into a computer. For sensitive
issues like sexual behavior, the participant used computer-assisted self-interview (CASI) to
enter responses directly into the computer.
Respondents were asked to provide a urine specimen to test for Chlamydia trachomatis, for
which they received $10. A more detailed description of Add Health STI testing is available
elsewhere (23). Specimens were tested for C. trachomatis per manufacturer instructions using
ligase chain reaction (LCR™) amplification technology in the Abbott LCx® Probe System
(Abbott Laboratories, Abbott Park, IL), except that specimens exceeding the recommended
volume were tested.
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The outcome variable was a positive C. trachomatis test result. Possible predictor variables
were derived from the self-reported demographic, behavior, perceived risk, and health care
factors available from the in-home interview.
Statistical analyses
We conducted analyses using Stata Version 7.0 (Stata Corporation, College Station, TX).
Evaluation of model fit and bootstrap estimates were obtained from unweighted data. All other
analyses accounted for Add Health’s complex survey design by using school as the primary
sampling unit, region of the country as the stratification variable, and post-stratification
weights.
Analyses were performed separately by gender to accommodate sex-specific differences in
predictors of STI and prevalence of chlamydial infection (24–27). In preliminary analyses, we
examined the frequency distribution of potential predictor characteristics and calculated
bivariate prevalence odds ratios (OR) and 95 percent confidence intervals (CI) to assess the
association between each characteristic and chlamydial infection.
For each gender, we developed three separate predictive models using either 1) the respondent’s
race/ethnicity; 2) the respondent’s most recent partner’s race/ethnicity; or 3) no information
on respondent’s or partner’s race/ethnicity to account for the racial/ethnic disparity in
prevalence. The initial starting models included one of the race/ethnicity components and all
variables with bivariate p<0.25. Variables with excessive missing data, extreme collinearity,
or uninformative distributions were excluded from the starting models, regardless of p-value.
Each model included only respondents with complete information on all variables in that full
model.
Predictive model development used unconditional multiple logistic regression for survey data
with a backwards elimination strategy (28). We removed variables one at a time from the model,
beginning with the variable with the largest p-value. The model-based c-statistic, the area under
the receiver operating characteristic (ROC) curve, was compared between successive models
to ensure that variable removal did not adversely affect model performance. A change in area
under the ROC curve<0.01 was acceptable. Backwards elimination stopped when all remaining
variables had p<0.05. We assessed the equality of the three ROC areas (29). We also examined
the models for collinearity and overly influential covariate patterns (30).
We created three sets of clinical risk scores from each final model. The first was a simple
summation of the beta coefficients for the models, reflecting the predicted probability of
infection. The second was a weighted risk score calculated by multiplying the regression
coefficients by two and rounding to the nearest integer. The third was an unweighted risk score
that assigned each risk category a value of one, regardless of its strength of association with
infection, and each reference category a value of zero. Sensitivity and specificity of each
predictive model and its risk scores were assessed at three hypothetical program-driven cutoffs
based on a maximum percentage of the population (≤70, ≤50, ≤30) to receive a diagnostic test.
We validated model and risk score performance using 1,000 bootstrap samples with
replacement (28), although this technique could not accommodate Add Health’s survey design.
RESULTS
Study population
Of the 18,924 Add Health participants in the nationally representative Wave I sample, 1,109
(5.9%) refused participation, 3,493 (18.5%) could not be located or were unable to participate,
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and 14,322 (75.7%) were located and agreed to participate in Wave III. Of these, 12,334
(86.1%) reported ever having vaginal intercourse. C. trachomatis results were available for
10,928 (88.6%) of the sexually experienced participants (57.7% of the original Wave I sample).
Reasons for unavailable test results included inability or refusal to provide a urine specimen,
processing errors due to shipping, or laboratory problems.
Among participants with chlamydia test results, 50.0 percent of the study sample was women
(Table 1). The majority (67.8%) was white, with representation of black (16.7%), Latino
(11.5%), Asian American (3.2%), and Native American (0.8%) women and men. The mean
age of participants was 21.9 years (standard error (SE), 0.12 years). The mean age at sexual
debut was 16.4 years (SE, 0.06 years) and the mean number of sex partners during the past
year was 1.8 partners (SE, 0.03 partners). On average, women had fewer partners (1.5 partners,
SE 0.04) than men (2.0 partners, SE 0.06).
Women
Bivariate analyses—The overall prevalence of chlamydial infection among sexually
experienced women was 5.1 percent (95% CI 4.2%, 6.0%). Women who were black (OR 5.7,
95% CI 3.9, 8.5) or Native American (OR 6.1, 95% CI 2.3, 16.1) were more likely to have
chlamydial infection as compared to whites (Table 2). Women reporting black partners (OR
6.9, 95% CI 4.5, 10.6) also were more likely to have chlamydial infection. When compared to
women with no sex partners in the past year, the relation between number of partners and
infection was nearly twice as strong for two or more sex partners (OR 7.4, 95% CI 2.8, 19.2)
than for one partner (OR 3.4, 95% CI 1.4, 8.5). While a moderate or high perceived risk of STI
(OR 5.5, 95% CI 3.1, 9.8) was indicative of infection, neither STI symptoms within the past
24 hours (OR 1.0, 95% CI 0.6, 1.8) nor STI symptoms (OR 1.0, 95% CI 0.7, 1.4), testing (OR
1.1, 95% CI 0.8, 1.5), or diagnosis (OR 1.6, 95% CI 1.0, 2.4) within the past year, showed
substantive association with prevalent chlamydial infection.
Multivariate analyses—We constructed three reference models for women that included
the race/ethnicity component (respondent’s race, partner’s race, or no race) and 17
characteristics with bivariate p<0.25. After removing variables that minimally predicted
infection, number of partners, perceived risk of STI, and student status consistently remained
important across the three final models (Table 3a). The final models with respondent race (area
under ROC curve=0.77) and partner race (area under ROC curve=0.75) information performed
comparably and both performed substantially better than the model without race information
(area under ROC curve=0.70). The areas under the three curves differed significantly (p
<0.001; Figure 1a).
Risk Scores—The weighted risk scores from the model with respondent race information
ranged from zero for a white woman, with no sex partners in the past year, low perceived risk
of STI, who was a current student, aged 22 – 24 years, to a score of 13 for a Native American
woman, with two or more sex partners in the past year, moderate or high perceived risk of STI,
not a current student, and was either younger than age 22 or older than age 24 years (Table
3a). Using the weighted risk score to identify no more than 50 percent of the population for
testing, the sensitivity of the model with respondent race information (84.1%) was slightly
higher than the model with partner race information (81.3%), but substantially higher than the
model with no race information (60.1%; Table 4a).
The performance of the three models varied markedly when stratified by race (Table 5a).
Among white women, the models had low sensitivity. Among black women, however, with
one exception the sensitivities of the models with respondent and partner race information were
above 90 percent; the model with no race information performed poorly. Testing ≤50 percent
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using the weighted risk score from the model without race information was 61.8 percent
sensitive among black women, compared to 99.4 percent in the race and 94.7 percent in the
partner race information models.
To illustrate the impact of the differing sensitivities across the three models, we examined the
estimated number of infections correctly identified in the general population of women aged
18 to 26 years (Table 6a). The race information model weighted risk score would correctly
identify 142,350 out of 142,776 infections among black women. The model without race
information would miss more than 50,000 of these infections. Among white women, the
difference in the number of missed infections between the models with and without race
information was fewer than 10,000. The number of women of all races without infection who
were identified for testing (i.e. false positives) was large, regardless of the model.
Men
Bivariate analyses—The overall prevalence of chlamydial infection among sexually
experienced men was 3.9 percent (95% CI 3.1%, 4.8%). Men who were black (OR 8.0, 95%
CI 4.9, 13.1), Native American (OR 5.7, 95% CI 2.1, 15.6), or Latino (OR 5.3, 95% CI 2.9,
9.9) were more likely to have chlamydial infection as compared to whites. Men reporting black
(OR 5.9, 95% CI 3.4, 10.4) or Latino (OR 3.5, 95% CI 1.6, 7.8) partners were also more likely
to have chlamydial infection (Table 2). Similar to women, a moderate or high perceived risk
of STI (OR 5.2, 95% CI 2.6, 10.4) was indicative of infection. Unlike women, STI symptoms
(OR 2.4, 95% CI 1.5, 3.8) or diagnosis (OR 2.6, 95% CI 1.4, 5.0) within the past year as well
as no recent antibiotic use (OR 2.9, 95% CI 1.4, 6.2) and shared housing (OR 2.3, 95% CI 1.5,
3.7) were linked to prevalent chlamydial infection.
Multivariate analyses—We constructed three reference models for men that included the
race/ethnicity component and 16 characteristics with bivariate p<0.25. A core set of
characteristics – perceived risk of STI, military history, shared housing, and high school degree
– remained important in all three models (Table 3b). The final respondent race (area under
ROC curve=0.74) and partner race (area under ROC curve=0.75) information models were
comparable, and superior to the model without race information (area under ROC curve=0.69).
The areas under the three curves differed significantly (p=0.02; Figure 1b).
Risk scores—The weighted risk scores from the model with respondent race information
ranged from zero for a white man, with low perceived risk of STI, no military history, lived
alone, graduated from high school, and accessed health care within the past year, to 12 for a
black man, with moderate or high perceived risk of STI, military experience, shared housing,
not a high school graduate, and had not recently accessed health care (Table 3b). Using a
weighted score to test ≤50 percent of those screened by the model with respondent race
information yielded a sensitivity of 82.5 percent and specificity of 55.3 percent (Table 4b).
The performance of these models also varied by race (Table 5b). Among black men, using
weighted risk scores to test ≤50 percent was 100 percent sensitive for the respondent race
information model, but only 71.4 percent sensitive for the no race information model. All
models had low sensitivity for white men
Using the survey weights to estimate the number of infections correctly identified in the general
population of men aged 18 to 26 years, the race information model weighted risk score would
correctly identify all 80,756 infections among black men (Table 6b). The model without race
information would identify only 54,152 of these infections. Again, the numbers of men tested
who did not have chlamydial infection was large.
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Using bootstrap techniques, validation of models for both women and men demonstrated
consistent performance over 1000 replications.
DISCUSSION
Current guidelines recommend annual universal testing of sexually active young women for
chlamydial infection (14,31), but only an estimated 55 – 66 percent of females aged 15 – 19
were screened in 2000 (15). Self-report of STI testing is even lower (16). One reason for low
screening rates may be that these guidelines require women to visit health care providers.
Community-based screening may expand screening coverage among young people who are
often uninsured and unlikely to access health care regularly (32–34). Community screening
may also promote testing programs for men and may be an effective way to lessen the racial/
ethnic disparity.
Our proposed screening criteria are unique because they were developed from a representative
sample of the population they are designed to serve. Additionally, the guidelines are available
for women and men. A combination of five characteristics for women (race/ethnicity, number
of sex partners in the past year, perceived risk of STI, current student status, and age) and six
characteristics for men (race/ethnicity, perceived risk of STI, military history, shared housing,
high school degree, and recent health care use) provide potentially useful screening tools.
However, implementation of these criteria may be problematic because of the inclusion of race-
related information. Applying these criteria to select no more than 50 percent of the population
for diagnostic testing could identify approximately 80 percent of infections in women and men.
Many uninfected people would be tested, but there is little evidence supporting durable distress
or harm after STI population screening (35). Also, fewer uninfected people would be tested
than would be tested under universal screening guidelines.
Add Health reinforces previous findings of discernible differences in infection prevalence
across racial/ethnic groups, with black and Native American females and black, Latino, and
Native American males, more likely to have a prevalent chlamydial infection than their white
counterparts. The Add Health design ensured that estimated effects were independent of
clinician reporting and health care seeking behavior – common explanations for racial/ethnic
differences in reported infection rates. Furthermore, the oversampling of some black and Latino
groups enhanced the precision of these estimates.
The two models developed with race/ethnicity information were similar in both constituent
characteristics and overall performance because of the strong correlation between a
respondent’s and partner’s race/ethnicity. In contrast, the performance of the model developed
without race/ethnicity information was greatly diminished. Despite the inclusion of numerous
covariates at the outset, no proxy for socioeconomic status (such as insurance or job status) or
other connection to elevated prevalence remained in the final models. Detailed data on sexual
networks or environmental characteristics that may address the disparity in infection were
unavailable in these data and would not be typically available for use in routine screening
settings.
Ideally, screening guidelines would identify individuals for testing based solely on risk
behaviors. Risk stratification appears to differ by race/ethnicity (36). Chlamydial infection is
increased among white young adults with traditional risk behaviors, but black young adults are
at high risk of chlamydial infection even when practicing behaviors that are low risk for white
youth (36). This observation may explain why the model without race/ethnicity information
performed poorly among non-white subpopulations. The models with race/ethnicity
information performed well among minority populations because nearly everyone was tested.
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The use of race/ethnicity in any STI screening algorithm is undoubtedly controversial (37).
Both inclusion and exclusion of race/ethnicity as a risk marker may have unintended adverse
consequences. Using the model with a race/ethnicity criterion ignores both contemporary and
historical context and may further marginalize minority communities, possibly leading to
stigmatization and perpetuation of inappropriate and incorrect stereotypes. Using the model
without race/ethnicity information would result in a dramatic reduction in the number of
persons appropriately tested and treated. In essence, selective screening without race/ethnicity
as a criterion deprives care for those with the highest prevalence.
The most satisfactory approach to deal with this conundrum is universal testing for persons in
this age group. Alternatively, because the primary risk factor for chlamydial infection is
encountering an infected partner, targeting screening to high prevalence areas also may be a
reasonable, cost-efficient strategy (38). This strategy would increase testing among minority
populations, but the primary determinant would be prevalence and geographical area, not race/
ethnicity.
Universal screening for chlamydial infection in men in this age group is not recommended in
the current CDC guidelines despite recognition of a potential benefit. Given limited resources
and the infrequency of health care visits for young adult men, selective community-based
screening may provide a reasonable option to expand screening to men. Our models and
associated risk scores provide one of the first algorithms to reach this group.
The validity of our results depends on the representativeness of the original school-based
sample, nonresponse to the Wave III follow-up survey, truthful reporting on sexual experience,
refusal or other problems that led to a missing outcome, and the characteristics of the diagnostic
test. The original sample included only students on school registers, but an evaluation of school
dropouts suggests any resultant bias in Add Health is small (39). Poststratification sample
weight adjustment accounted for the 24 percent of Wave I participants who could not be located
for Wave III, a bias that was also small (40). Both the frequency and validity of responses to
sensitive questions about sexual experiences were likely improved through the use of CASI
(41–45). Additionally, participants who did and did not provide urine specimens for STI testing
were similar (46). Earlier analyses show prevalence estimates were robust to differences in
characteristics of non-respondents and diagnostic test performance (4). Imperfect sensitivity
may have slightly reduced estimates in low prevalence populations and slightly increased
estimates in high prevalence populations (4).
Young adults in the US are at risk of chlamydial infection. Minority women and men are
disproportionately affected. Broadening screening programs beyond clinic settings may reduce
the STI burden by increasing screening and treatment. Universal screening should be
implemented in high prevalence regions. In low prevalence regions, selective screening may
suffice. When selectively screening, locally relevant information will be critical for
determining whether the use of race/ethnicity is appropriate to improve the guidelines’
performance. The value of screening men must be duly considered. The performance of these
selective screening guidelines, which require neither medical nor laboratory information to
identify individuals for urine-based diagnostic testing, supports the practicality of community-
based chlamydial screening for women and men, although neither the effectiveness nor
programmatic feasibility of these guidelines has been determined. With greater screening
coverage and treatment for the infected, the incidence and prevalence of chlamydial infection
in young people, and the sequelae manifest throughout adulthood, will likely diminish.
ABBREVIATIONS
Add Health  
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Figure 1a. Sensitivity of Predicted Probabilities by Percentage of Population Tested among
Sexually Experienced Women, National Longitudinal Study of Adolescent Health, 2001 –
2002. When testing 50% or less of the women, the sensitivity of the model with race information
is 81.7% (test 45%), the sensitivity of the model with partner race information is 82.0% (test
43%), and the sensitivity of the model without race information is 76.6% (test 49%). The areas
under the corresponding ROC curves differ significantly (p<0.001).
Figure 1b. Sensitivity of Predicted Probabilities by Percentage of Population Tested among
Sexually Experienced Men, National Longitudinal Study of Adolescent Health, 2001 – 2002.
When testing 50% or less of the men, the sensitivity of the model with race information is
83.3% (test 48%), the sensitivity of the model with partner race information is 82.5% (test
48%), and the sensitivity of the model without race information is 78.1% (test 49%). The areas
under the corresponding ROC curves differ significantly (p=0.02).
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Table 1
Characteristics of Sexually Experienced Respondents with Chlamydia trachomatis Test Results by Gender, National
Longitudinal Study of Adolescent Health, 2001 – 2002
Women (n=5854) Men (n=5074)
Characteristic Number of Participants Weighted Percent Number of Participants Weighted Percent
Chlamydial infection
 Positive 316 5.1 236 3.9
 Negative 5538 94.9 4838 96.1
Race/ethnicity
 White 3178 68.2 2770 67.5
 Black 1364 17.1 1033 16.3
 Latino 909 11.0 864 11.9
 Asian American 337 2.9 343 3.4
 Native American 53 0.8 50 0.9
Partner race/ethnicity
 White 2534 62.0 2285 66.0
 Black 1192 19.6 6387 13.0
 Latino 739 11.1 595 12.3
 Other 427 7.2 446 8.7
Region
 South 2216 38.8 1897 40.4
 Outside South 3537 61.2 3101 59.6
Age, years
 18 – 21 2356 45.6 1775 42.5
 22 – 24 3191 49.2 2942 49.4
 25 – 26 307 5.2 357 8.1
Age at sexual debut, years
 10 – 16 3081 56.0 2623 53.6
 17 – 25 2749 45.0 2420 46.4
Number of sex partners,
past year
 0 459 6.9 489 9.3
 1 3711 65.6 2604 51.6
 2 – 50 1629 27.5 1914 39.1
Sexuality
 100% heterosexual 5600 96.1 5000 98.9
 Not 100% heterosexual 227 3.9 58 1.1
Perceived risk of prevalent
STI
 Low 5398 96.7 4659 96.1
 Moderate or high 211 3.3 187 3.9
Perceived risk of lifetime
HIV infection
 Low 5647 97.7 4844 96.6
 Moderate or high 148 2.3 182 3.4
STI symptoms, past year
 Symptoms 1653 28.7 451 9.3
 No Symptoms 4165 71.3 4580 90.7
STI test, past year
 Test 2172 36.9 902 18.2
 No test 3631 63.1 4128 81.8
STI diagnosis, past year
 Diagnosis 840 14.1 228 4.3
 No diagnosis 4919 85.8 4765 95.7
Insurance status
 Insurance 4612 77.1 3615 71.0
 No insurance 1211 22.9 1431 29.0
Recent health care use
 Within past year 5473 93.9 3650 72.5
 Longer than past year 375 6.1 1406 27.5
Forgone care, past year*
 Forgone care 1422 23.3 1261 24.3
 No forgone care 4428 76.7 3809 75.7
Antibiotic use, past 30 days
 Antibiotic 943 16.8 537 11.0
 No antibiotic 4904 83.2 4531 89.0
Hormonal contraception
use, current
 Contraception 3724 64.8 3057 62.2
 No Contraception 2101 35.2 1977 37.8
Condom use, past year
 100% use 1440 23.6 1633 32.1
 Not 100% use 4352 76.4 3379 67.9
Pregnancy history, women
only
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Women (n=5854) Men (n=5074)
Characteristic Number of Participants Weighted Percent Number of Participants Weighted Percent
 Ever pregnant 2477 42.0
 Never pregnant 3331 58.0
Marital status
 Married 1356 23.4 806 15.1
 Not married 4498 76.6 4266 84.9
Housing
 Shared housing 2592 42.7 2712 52.7
 Live alone 3262 57.3 2360 47.3
Student status
 Current student 2224 37.2 1606 31.0
 Not a current student 3629 62.8 3465 69.0
High school graduate
 Graduate 5335 90.0 4529 88.0
 Not a graduate 516 10.0 542 12.0
Military history
 Ever military 97 1.5 367 6.8
 Never military 5752 98.5 4702 93.2
Employment status
 Job 3989 67.8 3764 74.4
 No job 1865 32.2 1310 25.6
Functional poverty, past
year
 Able to pay rent, utilities 5502 93.8 4841 95.9
 Unable to pay rent,
utilities
323 6.2 205 4.1
STI, sexually transmitted infection
*
Forgone care defined by response to question “Has there been any time in the past 12 months when you thought you should get medical care, but you
did not?”
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Table 2
Bivariate Association of Prevalent Chlamydial Infection and Potential Predictor Characteristics among Sexually
Experienced Respondents by Gender, National Longitudinal Study of Adolescent Health, 2001 – 2002
Characteristic Women Men
Prevalence Odds Ratio (95% CI) Prevalence Odds Ratio (95% CI)
Race/ethnicity
 White 1.0 1.0
 Black 5.7 (3.9 – 8.5) 8.0 (4.9 –13.1)
 Latino 1.8 (1.1 – 2.9) 5.3 (2.9 – 9.9)
 Asian American 1.2 (0.5 – 2.8) 1.0 (0.3 – 2.8)
 Native American 6.1 (2.3 – 16.1) 5.7 (2.1 – 15.6)
p < 0.001 p < 0.001
Partner’s race/ethnicity
 White 1.0 1.0
 Black 6.9 (4.5 – 10.5) 5.9 (3.4 – 10.4)
 Latino 2.3 (1.0 – 5.0) 3.5 (1.6 – 7.8)
 Other 1.7 (0.8 – 3.8) 1.6 (0.5 – 5.1)
p < 0.001 p < 0.001
Region
 South 1.4 (0.9 – 2.1) 1.7 (1.1 – 2.8)
 Outside South 1.0 1.0
p = 0.10 p = 0.03
Age, years
 18 – 21 1.5 (1.1 – 2.2) 1.0 (0.6 – 1.5)
 22 – 24 1.0 1.0
 25 – 26 2.1 (1.3 – 3.5) 0.8 (0.4 – 1.6)
p < 0.01 p = 0.82
Age at sexual debut, years
 10 – 16 1.4 (1.0 – 2.0) 2.0 (1.3 –3.0)
 17 – 25 1.0 1.0
p = 0.04 p < 0.01
Number of sex partners, past year
 0 1.0 1.0
 1 3.4 (1.4 – 8.5) 1.6 (0.7 – 3.3)
 2 – 50 7.4 (2.8 –19.2) 2.3 (1.1 – 5.0)
p < 0.001 p = 0.04
Sexuality
 100% heterosexual 1.0 1.0
 Not 100% heterosexual 0.6 (0.2 – 1.6) 2.6 (0.8 – 8.8)
p = 0.31 p = 0.11
Perceived risk of prevalent STI
 Low 1.0 1.0
 Moderate or high 5.5 (3.1 – 9.8) 5.2 (2.6 –10.4)
p < 0.001 p < 0.001
Perceived risk of HIV infection
 Low 1.0 1.0
 Moderate or high 2.0 (0.9 – 4.5) 2.4 (1.1 – 5.1)
p = 0.09 p = 0.03
STI symptoms, past year
 Symptoms 1.0 (0.7 – 1.4) 2.4 (1.5 – 3.8)
 No Symptoms 1.0 1.0
p = 0.99 p < 0.001
STI test, past year
 Test 1.1 (0.8 – 1.5) 1.1 (0.8 – 1.9)
 No test 1.0 1.0
p = 0.53 p = 0.68
STI diagnosis, past year
 Diagnosis 1.6 (1.0 – 2.4) 2.6 (1.4 – 5.0)
 No diagnosis 1.0 1.0
p = 0.04 p < 0.01
Insurance status
 Insurance 1.0 1.0
 No insurance 1.4 (0.99 – 2.0) 1.9 (1.2 – 3.0)
p = 0.08 p = 0.01
Recent health care use
 Within past year 1.0 1.0
 Longer than past year 0.8 (0.4 – 1.6) 1.4 (0.99 – 2.0)
p = 0.60 p = 0.08
Forgone care, past year*
 Forgone care 1.2 (0.8 – 1.6) 1.2 (0.8 – 1.8)
 No forgone care 1.0 1.0
p = 0.32 p = 0.34
Antibiotic use, past 30 days
 Antibiotic 1.0 1.0
 No antibiotic 1.5 (0.99 – 2.3) 2.9 (1.4 – 6.2)
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Characteristic Women Men
Prevalence Odds Ratio (95% CI) Prevalence Odds Ratio (95% CI)
p = 0.06 p = 0.01
Hormonal contraception use
 Contraception 1.0 1.0
 No Contraception 1.4 (0.9 – 2.0) 1.1 (0.8 – 1.6)
p = 0.11 p = 0.43
Condom use, past year
 100% use 1.0 1.0
 Not 100% use 1.0 (0.7 – 1.5) 0.9 (0.6 – 1.4)
p = 0.81 p = 0.65
Pregnancy history, women only
 Never pregnant 1.0




 Not married 2.6 (1.5 – 4.4) 1.3 (0.8 – 3.0)
p < 0.01 p = 0.30
Housing
 Shared housing 1.3 (0.9 – 1.9) 2.3 (1.5 – 3.7)
 Live alone 1.0 1.0
p = 0.17 p < 0.001
Student status
 Current student 1.0 1.0
 Not a current student 1.8 (1.2 – 2.6) 1.6 (1.1 – 2.6)
p < 0.01 p = 0.03
High school graduate
 Graduate 1.0 1.0
 Not a graduate 1.4 (0.9 – 2.1) 2.2 (1.3 – 3.6)
p = 0.17 p < 0.01
Military history
 Never military 1.0 1.0
 Ever military 2.9 (1.2 – 5.5) 1.6 (0.9 – 3.0)
p = 0.01 p = 0.13
Employment status
 Job 1.0 1.0
 No job 1.3 (0.9 – 1.8) 1.8 (1.2 – 2.8)
p = 0.14 p = 0.01
Functional poverty, past year
 Able to pay rent, utilities 1.0 1.0
 Unable to pay rent, utilities 1.4 (0.8 – 2.5) 1.1 (0.5 – 2.5)
p = 0.21 p = 0.81
CI, confidence interval; STI, sexually transmitted infection p-value for adjusted Wald F-test
*
Forgone care defined by response to question “Has there been any time in the past 12 months when you thought you should get medical care, but you
did not?”


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ann Epidemiol. Author manuscript; available in PMC 2009 July 1.
